Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
PERI
ANTEROGEN
★

Anterogen 2025 Sales ↑, Operating Loss ↓, DFU Phase 3 Ongoing

  05/15/2026, 03:48 PM
PERI
ANTEROGEN
★★

Anterogen: 1Q26 Sales Up 32%, Japan Approval for ALLO-ASC-EB

  05/15/2026, 03:43 PM
PERI
ANTEROGEN
★★★

Anterogen: Japanese Approval for EB Therapy AlloStem and Revenue Growth

  05/15/2026, 08:39 AM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.